Clinical trial
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212 · Pfizer, Industry · Active, not recruiting
Key facts
| NCT number | NCT05035212 |
|---|---|
| Title | Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. |
| Official title | A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS |
| Acronym | RENOIR |
| Lead sponsor | Pfizer, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lower Respiratory Tract Illness |
| Intervention type | Biological |
| Interventions | RSVpreF, Placebo |
| Enrollment | 38,861 |
| Start date | Aug 31, 2021 |
| Primary completion | Jan 18, 2027 |
| Completion | Jan 18, 2027 |
| First posted | Sep 5, 2021 |
| Last update posted | Jan 28, 2026 |
| Countries | Argentina, Canada, Finland, Japan, Netherlands, South Africa, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: